High neutrophil to lymphocyte ratio as a predictor for hyperprogressive disease in patients with metastatic non-small cell lung cancer treated with pembrolizumab as a second line.

e21546Background: In this study we evaluated the incidence of early non-responders (which are potential hyper-progressors (HP)) and its relation to Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymph...